EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Target Attainment and Clinical and Biochemical Parameters Associated with the Pharmacokinetics of 12 Tyrosine Kinase Inhibitors

Zaid N Al Shirity, Paola Mian, Anouk Dontje, Anthonie J van der Wekken, Esther Broekman, Saskia K Klein, Daan J Touw, Thijs H Oude Munnink, Marjolijn N Lub-de Hooge, Bahez Gareb

Clinical Pharmacokinetics · 2026-11 · 65 (11) · 1687-1703

DOI: 10.1007/s40262-026-01684-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacokinetics, online erschienen am 04.09.2026. Verfasst von Zaid N Al Shirity und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen (UMCG), University of Groningen, Hanzeplein 1, 9713 GZ, Groning…. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Neoplasms, Antineoplastic Agents. Die Arbeit nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective Tyrosine kinase inhibitors (TKIs) are targeted cancer therapies. However, TKIs are still limited due to their high inter-individual variability. This study evaluated target attainment using therapeutic drug monitoring (TDM) data from 12 TKIs, and investigated biochemical and patient-related characteristics influencing TKI pharmacokinetics (PK)

Methods

This single-centre retrospective study included cancer patients treated with TKIs between January 2020 and August 2024. Demographic, clinical, and biochemical data were extracted from electronic health records. Univariate and multivariate linear mixed models were used to identify factors associated with TKI PK.

Results

A total of 1237 TKI concentrations from 309 patients were included. Target attainment percentages were: 74.6% for alectinib; 70% for bosutinib; 49.9–61.9% for imatinib depending on the indication; 88.9% for nilotinib; 50% for pazopanib; 50% for ponatinib; 89.5% for regorafenib; 26.6% for sunitinib; ibrutinib, lenvatinib and trametinib had too few data for formal assessment; 40–87.5% for dasatinib, depending on indication and parameter ( C _max or C _min). A mixed linear model analysis identified key parameters correlated with TKI concentrations. Glomerular filtration rate was correlated with alectinib, imatinib, and sunitinib. Alkaline phosphatase (ALP), bilirubin, and Gamma-GT correlated with alectinib and ALP with imatinib. Albumin and thrombocytes correlated with imatinib, thrombocytes with pazopanib, absolute neutrophiles count (ANC) with ponatinib, and haematocrit with regorafenib.

Conclusion

Target attainment was suboptimal for most TKIs, supporting the need for TDM-guided optimisation and individualised dosing. Associations between TKI exposure and renal, hepatic, and haematological parameters further support personalised treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsNeoplasmsAntineoplastic AgentsHumansFemaleRetrospective StudiesMaleDrug MonitoringMiddle AgedAgedAdultAged, 80 and overTyrosine Kinase Inhibitors

Substanzen

Protein Kinase InhibitorsAntineoplastic AgentsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen (UMCG), University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
  • Pharmacometrics Expertise Center of the Northern Netherlands, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Department of Paediatrics, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The Netherlands.
  • Department of Pulmonology and Tuberculosis, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
  • Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Zitieren

APA

Shirity, Z. N. A., Mian, P., Dontje, A., van der Wekken, A. J., Broekman, E., Klein, S. K., Touw, D. J., Munnink, T. H. O., Hooge, M. N. L., & Gareb, B. (2026). Target Attainment and Clinical and Biochemical Parameters Associated with the Pharmacokinetics of 12 Tyrosine Kinase Inhibitors. Clinical Pharmacokinetics, 65(11), 1687-1703. https://doi.org/10.1007/s40262-026-01684-8

Vancouver

Shirity ZNA, Mian P, Dontje A, van der Wekken AJ, Broekman E, Klein SK, et al. Target Attainment and Clinical and Biochemical Parameters Associated with the Pharmacokinetics of 12 Tyrosine Kinase Inhibitors. Clinical Pharmacokinetics. 2026;65(11):1687-1703. doi:10.1007/s40262-026-01684-8

BibTeX
@article{Shirity2026,
  author = {Shirity, Zaid N Al and Mian, Paola and Dontje, Anouk and van der Wekken, Anthonie J and Broekman, Esther and Klein, Saskia K and Touw, Daan J and Munnink, Thijs H Oude and Hooge, Marjolijn N Lub-de and Gareb, Bahez},
  title = {Target Attainment and Clinical and Biochemical Parameters Associated with the Pharmacokinetics of 12 Tyrosine Kinase Inhibitors},
  journal = {Clinical Pharmacokinetics},
  year = {2026},
  volume = {65},
  number = {11},
  pages = {1687--1703},
  doi = {10.1007/s40262-026-01684-8}
}
Kostenlos starten →